Blood Biomarkers for Alzheimer’s Dementia Diagnosis

키워드

참고문헌 (50)

1. Luu L, "The Alzheimer’s disease amyloid precursor protein and its neuritogenic actions", Curr Alzheimer Res, 18, pp.772~786 (2021)[DOI]
2. Hansson O, "The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis : a review", Alzheimers Dement, 14, pp.1313~1333 (2018)[DOI]
3. Wegmann S, "A current view on Tau protein phosphorylation in Alzheimer’s disease", Curr Opin Neurobiol, 69, pp.131~138 (2021)[DOI]
4. Babapour Mofrad R, "Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status", Alzheimers Res Ther, 13, pp.133~ (2021)[DOI]
5. Choi Y, "Endogenous Aβ peptide promote Aβ oligomerization tendency of spiked synthetic Aβ in Alzheimer’s disease plasma", Mol Cell Neurosci, 111, pp.103588~ (2021)[DOI]
6. Pyun JM, "Plasma amyloid-β oligomerization tendency predicts amyloid PET positivity", Clin Interv Aging, 16, pp.749~755 (2021)[DOI]
7. Konietzko U, "AICD nuclear signaling and its possible contribution to Alzheimer’s disease", Curr Alzheimer Res, 9, pp.200~216 (2012)[DOI]
8. Irwin DJ, "Parkinson’s disease dementia : convergence of α-synuclein, tau and amyloid-β pathologies", Nat Rev Neurosci, 14, pp.626~436 (2013)[DOI]
9. Youn YC, "Blood amyloid-β oligomerization as a biomarker of Alzheimer’s disease : a blinded validation study", J Alzheimers Dis, 75, pp.493~499 (2020)[DOI]
10. Meng X, "Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease", Alzheimers Res Ther, 11, pp.89~ (2019)[DOI]
11. An SSA, "Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42", Alzheimers Res Ther, 9, pp.86~ (2017)[DOI]
12. Ivanov SM, "Cellular polyamines condense hyperphosphorylated Tau, triggering Alzheimer’s disease", Sci Rep, 10, pp.10098~ (2020)[DOI]
13. Lan G, "Association of presynaptic loss with Alzheimer’s disease and cognitive decline", Ann Neurol, 92, pp.1001~1015 (2022)[DOI]
14. Williams SM, "Oligomeric alpha-synuclein and beta-amyloid variants as potential biomarkers for Parkinson’s and Alzheimer’s diseases", Eur J Neurosci, 43, pp.3~16 (2016)[DOI]
15. Meneses A, "TDP-43 Pathology in Alzheimer’s disease", Mol Neurodegener, 16, pp.84~ (2021)[DOI]
16. Zheng Y, "Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer’s disease", Theranostics, 12, pp.2095~2114 (2022)[DOI]
17. Hugo J, "Dementia and cognitive impairment : epidemiology, diagnosis, and treatment", Clin Geriatr Med, 30, pp.421~442 (2014)[DOI]
18. Harris LD, "The ubiquitin system in Alzheimer’s disease", Adv Exp Med Biol, 1233, pp.195~221 (2020)[DOI]
19. Ruan Z, "Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons", Brain, 144, pp.288~309 (2021)[DOI]
20. Hu S, "Molecular chaperones and Parkinson’s disease", Neurobiol Dis, 160, pp.105527~ (2021)[DOI]
21. Varesi A, "The potential role of gut microbiota in Alzheimer’s disease : from diagnosis to treatment", Nutrients, 14, pp.668~ (2022)[DOI]
22. Jiang C, "The gut microbiota and Alzheimer’s disease", J Alzheimers Dis, 58, pp.1~15 (2017)[DOI]
23. Chong JR, "Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease : a focused review on recent advances", J Neurol Neurosurg Psychiatry, 92, pp.1231~1241 (2021)[DOI]
24. Leuzy A, "Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer’s disease", Curr Opin Neurol, 34, pp.266~274 (2021)[DOI]
25. Hansson O, "Advantages and disadvantages of the use of the CSF amyloid β(Aβ)42", 40 ratio in the diagnosis of Alzheimer’s disease, 2019, pp.11, 34~
26. Cervellati C, "Serum beta-secretase 1(BACE1)activity as candidate biomarker for late-onset Alzheimer’s disease", Geroscience, 42, pp.159~167 (2020)[DOI]
27. Preische O, "Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease", Nat Med, 25, pp.277~283 (2019)[DOI]
28. Mavroudis I, "YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer’s disease", Medicina(Kaunas), 58, pp.60~ (2021)[DOI]
29. Karol Kowalski, "Brain-Gut-Microbiota Axis in Alzheimer’s Disease", Journal of Neurogastroenterology and Motility (JNM), 25(1), pp.48~60 (2019), 대한소화기 기능성질환∙운동학회[DOI]
30. Moscoso A, "Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease", JAMA Neurol, 78, pp.396~406 (2021)[DOI]
31. Rojas JC, "Plasma neurofilament light chain predicts progression in progressive supranuclear palsy", Ann Clin Transl Neurol, 3, pp.216~225 (2016)[DOI]
32. Katayama T, "Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy", Alzheimers Res Ther, 13, pp.163~ (2021)[DOI]
33. Tarawneh R, "Visinin-like protein-1 : diagnostic and prognostic biomarker in Alzheimer disease", Ann Neurol, 70(2), pp.274~285 (2011)[DOI]
34. Sturchio A, "High soluble amyloid-β42 predicts normal cognition in amyloid-positive individuals with Alzheimer’s disease-causing mutations", J Alzheimers Dis, 90, pp.333~348 (2022)[DOI]
35. Mizoi M, "Distinction between mild cognitive impairment and Alzheimer’s disease by CSF amyloid β40 and β42, and protein-conjugated acrolein", Clin Chim Acta, 430, pp.150~155 (2014)[DOI]
36. Mulugeta E, "CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies", J Neurol Neurosurg Psychiatry, 82, pp.160~164 (2011)[DOI]
37. Xu Y, "Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer’s disease and amnestic mild cognitive impairment", Eur J Neurol, 27, pp.1429~1435 (2020)[DOI]
38. Oeckl P, "Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment", J Alzheimers Dis, 67, pp.481~488 (2019)[DOI]
39. Wang X, "Elevated galectin-3 levels in the serum of patients with Alzheimer’s disease", Am J Alzheimers Dis Other Demen, 30, pp.729~732 (2015)[DOI]
40. Wang MJ, "Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease", Alzheimers Res Ther, 9, pp.98~ (2017)[DOI]
41. Guo Y, "Corrigendum : recent advances in the application peptide and peptoid in diagnosis biomarkers of Alzheimer’s disease in blood", Front Mol Neurosci, 15, pp.865110~ (2022)[DOI]
42. Shi Y, "Potential roles of extracellular vesicles as diagnosis biomarkers and therapeutic approaches for cognitive impairment in Alzheimer’s disease", J Alzheimers Dis, 87, pp.1~15 (2022)[DOI]
43. Olsson B, "CSF and blood biomarkers for the diagnosis of Alzheimer’s disease : a systematic review and meta-analysis", Lancet Neurol, 15, pp.673~684 (2016)[DOI]
44. Jia L, "Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage", Alzheimers Dement, 17, pp.49~60 (2021)[DOI]
45. Serrano-Pozo A, "APOE and Alzheimer’s disease : advances in genetics, pathophysiology, and therapeutic approaches", Lancet Neurol, 20, pp.68~80 (2021)[DOI]
46. 박정오, "Apolipoprotein E 유전자형과 알츠하이머형 치매의 통계적인 고찰", 대한임상검사과학회지, 36(2), pp.110~114 (2004), 대한임상검사과학회
47. Jiang C, "The gut microbiota and Alzheimer’s disease", J Alzheimers Dis, 58, pp.1~15 (2017)[DOI]
48. Leuzy A, "Blood-based biomarkers for Alzheimer’s disease", EMBO Mol Med, 14, pp.e14408~ (2022)[DOI]
49. Zetterberg H, "Blood-based molecular biomarkers for Alzheimer’s disease", Mol Brain, 12, pp.26~ (2019)[DOI]
50. Sharma L, "Promising protein biomarkers in the early diagnosis of Alzheimer’s disease", Metab Brain Dis, 37, pp.1727~1744 (2022)[DOI]

관련 논문AI추천